The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

Secondary prevention for lung cancer involves screening methods that aim to detect the disease in its early stages, before ...

AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.

The coveted designation for GSK5764227 (GSK'227, previously known as HS-20093) is for the use of the ADC to treat relapsed or refractory extensive-stage small-cell lung cancer (SCLC) and comes ...

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced that it has entered into exclusive license ...

Researchers conducted a retrospective study to examine the prognostic roles of Neutrophil-to-Lymphocyte Ratio (NLR) and ...

Individualized cancer vaccines and antibody-drug conjugates will be among the dominant biotech innovations in cancer next ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

For decades, treating lung cancer has been like trying to hit a moving target in the dark. Just when doctors think they've found an effective treatment, the cancer adapts and escapes. Now, a team of ...

This study suggests that immunotherapy may not be the optimal ... New, Rare Type of Small Cell Lung Cancer Identified Sep. 11, 2024 — A team of doctors and researchers have identified a new ...

Ryan Nguyen, DO, physician and researcher at the University of Illinois Chicago, emphasizes the transformative impact of immunotherapy in non–small cell lung cancer (NSCLC) and the need for precise ...

Small cell lung cancer ("SCLC") is another target, however, while Gilead believes trodelvy is now "standard of care" ("SoC") ...